Distinguishing neuroendocrine tumor grade 3 from neuroendocrine carcinoma in gastroenteropancreatic high-grade neoplasms
Endocrine Oncology · 01.01.2025 · 5 (1)
DOI: 10.1530/eo-25-0065 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Oncology, online erschienen am 09.12.2025. Verfasst von Zandra Ankers und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
High-grade neuroendocrine neoplasms (NENs) with a Ki-67 index >20% are currently classified as either grade 3 neuroendocrine tumors (NET G3) or neuroendocrine carcinomas (NEC). This study evaluates whether this subclassification is of diagnostic and prognostic significance.
Design
We analyzed 98 high-grade NENs from 87 patients, categorized into NET G3 (n = 19), NEC (n = 76), and equivocal cases (n = 3).
Methods
Histopathologic features, Ki-67 index, p53 and RB1 immunohistochemistry, growth patterns, necrosis, and somatostatin receptor type 2 (SSTR2) expression were assessed. Survival analyses were performed using Kaplan–Meier methods.
Results
NEC patients were older, had higher Ki-67 indices, and more often displayed solid growth, while NET G3 showed organoid architecture. Aberrant p53 and RB1 expression were significantly more common in NECs (P = 0.001 and P < 0.001). NET G3 patients had significantly longer overall survival than NEC patients (P = 0.03). Within NECs, tumor origin influenced prognosis: colorectal NECs had better outcomes (HR = 0.494, P = 0.027), while cancer of unknown primary (CUP) was associated with worse survival (HR = 2.033, P = 0.022). Notably, 81% of NECs expressed SSTR2, suggesting potential diagnostic and therapeutic relevance.
Conclusions
NET G3 and NEC show distinct clinicopathologic and prognostic profiles. Tumor origin offers additional stratification within NECs, while SSTR2 expression may inform targeted approaches. These findings underscore the need for nuanced classification and personalized management of high-grade NENs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden.
- Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
- Department of Breast, Endocrine Tumors, and Sarcoma, Karolinska University Hospital, Stockholm, Sweden.
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
ORCID-Profile: Adam Stenman, C Christofer Juhlin
Zitieren
APA
Ankers, Z., Hellgren, L. S., Stenman, A., Zedenius, J., & Juhlin, C. C. (2025). Distinguishing neuroendocrine tumor grade 3 from neuroendocrine carcinoma in gastroenteropancreatic high-grade neoplasms. Endocrine Oncology, 5(1). https://doi.org/10.1530/eo-25-0065
Vancouver
Ankers Z, Hellgren LS, Stenman A, Zedenius J, Juhlin CC. Distinguishing neuroendocrine tumor grade 3 from neuroendocrine carcinoma in gastroenteropancreatic high-grade neoplasms. Endocrine Oncology. 2025;5(1). doi:10.1530/eo-25-0065
BibTeX
@article{Ankers2025,
author = {Ankers, Zandra and Hellgren, L Samuel and Stenman, Adam and Zedenius, Jan and Juhlin, C Christofer},
title = {Distinguishing neuroendocrine tumor grade 3 from neuroendocrine carcinoma in gastroenteropancreatic high-grade neoplasms},
journal = {Endocrine Oncology},
year = {2025},
volume = {5},
number = {1},
doi = {10.1530/eo-25-0065}
}
EUVIMED